Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity
- PMID: 15855355
- DOI: 10.1124/jpet.105.083436
Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity
Abstract
In conscious rats, intravenous (i.v.) administration of the hexapeptide Ac-RYYRWK-NH(2), a partial agonist of the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor, produces a selective water diuresis without marked cardiovascular or behavioral effects. The present study examined the in vitro and in vivo pharmacodynamic profile of the novel and potentially metabolically stable NOP receptor ligand ZP120 (Ac-RYYRWKKKKKKK-NH(2)), which was created by conjugation of a structure-inducing probe (SIP) (i.e., K(6) sequence) to Ac-RYYRWK-NH(2). In cells transfected with human NOP receptors, both Ac-RYYRWK-NH(2) and ZP120 displaced [(3)H]N/OFQ (both peptides, pK(i) = 9.6), and similar to N/OFQ inhibited forskolin-induced cAMP formation (Ac-RYYRWK-NH(2), pEC(50) = 9.2; ZP120, 9.3; N/OFQ, 9.7). In the mouse vas deferens assay (MVD), Ac-RYYRWK-NH(2) and ZP120 behaved as partial agonists, inhibiting electrically induced contractions with similar pEC(50) values (9.0 and 8.6, respectively) but with submaximal efficacy compared with N/OFQ. In MVD, both peptides blocked the responses to N/OFQ, with ZP120 being approximately 50-fold more potent than Ac-RYYRWK-NH(2). In vivo, dose-response studies in rats showed that at doses (i.v. bolus or i.v. infusion) that produced a sodium-potassium-sparing aquaresis, ZP120 and Ac-RYYRWK-NH(2) elicited a mild vasodilatory response without reflex tachycardia. However, the renal responses to ZP120 were of greater magnitude and duration. Finally, each peptide blocked the bradycardia and hypotension to N/OFQ in conscious rats, but the effect of ZP120 was of much greater duration. Together, these findings demonstrate that ZP120 is a novel, functionally selective SIP-modified NOP receptor partial agonist with increased biological activity and sodium-potassium-sparing aquaretic activity, the actions of which may be useful in the management of hyponatremia/hypokalemia in water-retaining states.
Similar articles
-
ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.Br J Pharmacol. 2008 Mar;153(6):1185-94. doi: 10.1038/sj.bjp.0707688. Epub 2008 Jan 14. Br J Pharmacol. 2008. PMID: 18193068 Free PMC article.
-
Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function.J Pharmacol Exp Ther. 2005 Aug;314(2):643-51. doi: 10.1124/jpet.104.082768. Epub 2005 Apr 26. J Pharmacol Exp Ther. 2005. PMID: 15855356
-
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.Br J Pharmacol. 2002 Oct;137(3):369-74. doi: 10.1038/sj.bjp.0704894. Br J Pharmacol. 2002. PMID: 12237257 Free PMC article.
-
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.Pharmacol Ther. 2014 Mar;141(3):283-99. doi: 10.1016/j.pharmthera.2013.10.011. Epub 2013 Nov 1. Pharmacol Ther. 2014. PMID: 24189487 Free PMC article. Review.
-
Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.Ann N Y Acad Sci. 2004 Oct;1025:398-403. doi: 10.1196/annals.1316.049. Ann N Y Acad Sci. 2004. PMID: 15542742 Review.
Cited by
-
Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid.RSC Adv. 2020 Mar 25;10(20):12089-12104. doi: 10.1039/d0ra01002b. eCollection 2020 Mar 19. RSC Adv. 2020. PMID: 35496622 Free PMC article.
-
Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists.Br J Pharmacol. 2022 Jan;179(2):287-300. doi: 10.1111/bph.15717. Epub 2021 Dec 12. Br J Pharmacol. 2022. PMID: 34705263 Free PMC article.
-
UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.CNS Neurosci Ther. 2011 Jun;17(3):178-98. doi: 10.1111/j.1755-5949.2009.00107.x. Epub 2010 May 18. CNS Neurosci Ther. 2011. PMID: 20497197 Free PMC article. Review.
-
ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.Br J Pharmacol. 2008 Mar;153(6):1185-94. doi: 10.1038/sj.bjp.0707688. Epub 2008 Jan 14. Br J Pharmacol. 2008. PMID: 18193068 Free PMC article.
-
Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.J Med Chem. 2016 Aug 11;59(15):7011-28. doi: 10.1021/acs.jmedchem.5b01499. Epub 2016 Mar 14. J Med Chem. 2016. PMID: 26878436 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Miscellaneous